HRP20211754T1 - Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova - Google Patents
Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova Download PDFInfo
- Publication number
- HRP20211754T1 HRP20211754T1 HRP20211754TT HRP20211754T HRP20211754T1 HR P20211754 T1 HRP20211754 T1 HR P20211754T1 HR P20211754T T HRP20211754T T HR P20211754TT HR P20211754 T HRP20211754 T HR P20211754T HR P20211754 T1 HRP20211754 T1 HR P20211754T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- cell
- expression vector
- tcr
- nucleic acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 23
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000013604 expression vector Substances 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102100021445 Monocarboxylate transporter 11 Human genes 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108091006609 SLC16A11 Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 and optionally Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096165P | 2014-12-23 | 2014-12-23 | |
| GB201423016 | 2014-12-23 | ||
| GBGB1501017.6A GB201501017D0 (en) | 2014-12-23 | 2015-01-21 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| EP19199125.6A EP3626731B1 (en) | 2014-12-23 | 2015-12-16 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211754T1 true HRP20211754T1 (hr) | 2022-03-04 |
Family
ID=66846825
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211754TT HRP20211754T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| HRP20211580TT HRP20211580T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| HRP20211753TT HRP20211753T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| HRP20192212TT HRP20192212T4 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| HRP20211327TT HRP20211327T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211580TT HRP20211580T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| HRP20211753TT HRP20211753T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| HRP20192212TT HRP20192212T4 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| HRP20211327TT HRP20211327T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
Country Status (29)
| Country | Link |
|---|---|
| US (11) | US12076380B2 (enExample) |
| EP (1) | EP4461371A3 (enExample) |
| JP (9) | JP7358299B2 (enExample) |
| KR (4) | KR102435015B1 (enExample) |
| AU (1) | AU2022268329A1 (enExample) |
| CL (1) | CL2021001479A1 (enExample) |
| CO (1) | CO2017003772A2 (enExample) |
| CR (1) | CR20210289A (enExample) |
| CY (5) | CY1122491T1 (enExample) |
| DK (1) | DK3236985T4 (enExample) |
| ES (5) | ES2900106T3 (enExample) |
| FI (1) | FI3236985T4 (enExample) |
| HR (5) | HRP20211754T1 (enExample) |
| HU (5) | HUE055489T2 (enExample) |
| IL (1) | IL281752A (enExample) |
| LT (5) | LT3545965T (enExample) |
| MA (6) | MA49157A (enExample) |
| MD (5) | MD3626729T2 (enExample) |
| MX (6) | MX2020011794A (enExample) |
| MY (2) | MY178137A (enExample) |
| PE (1) | PE20211740A1 (enExample) |
| PL (4) | PL3626731T3 (enExample) |
| PT (5) | PT3616706T (enExample) |
| RS (1) | RS62575B1 (enExample) |
| SG (2) | SG10202102698VA (enExample) |
| SI (2) | SI3616706T1 (enExample) |
| TW (3) | TW202321273A (enExample) |
| UA (1) | UA124331C2 (enExample) |
| ZA (1) | ZA201701762B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49157A (fr) * | 2014-12-23 | 2021-06-02 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| CN114720691B (zh) * | 2022-05-10 | 2022-12-09 | 深圳粒影生物科技有限公司 | 一种检测生物标志物的试剂盒及其制备方法和应用 |
| CN119391711A (zh) * | 2024-10-17 | 2025-02-07 | 合肥综合性国家科学中心大健康研究院 | 小蛋白UFD1s及其在预防、治疗和诊断非酒精性脂肪性肝炎中的应用 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| NZ192465A (en) | 1978-12-22 | 1983-09-30 | Biogen Nv | Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| WO2001044279A2 (en) | 1999-12-17 | 2001-06-21 | Chiron Corporation | Mammalian dishevelled-associated proteins |
| AU2001232204A1 (en) | 2000-02-22 | 2001-09-03 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP2316950A1 (en) | 2000-03-27 | 2011-05-04 | Technion Research and Development Foundation, Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
| AU2001275246B2 (en) | 2000-06-05 | 2006-06-29 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| AU2001276018A1 (en) | 2000-07-20 | 2002-02-05 | Regents Of The University Of Minnesota | Radiolabeled immunotoxins |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20050053918A1 (en) * | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US20070134261A1 (en) * | 2001-12-03 | 2007-06-14 | Hancock Robert E | Effectors of innate immunity |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| US20040091503A1 (en) * | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| WO2004018667A1 (ja) | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ペプチド及びこれを含む医薬 |
| EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
| ES2327229T3 (es) | 2002-11-09 | 2009-10-27 | Immunocore Ltd. | Presentacion del receptor de linfocitos t. |
| US20040096982A1 (en) | 2002-11-19 | 2004-05-20 | International Business Machines Corporation | Methods and apparatus for analysis of mass spectra |
| EP1998177A3 (en) | 2003-01-06 | 2009-02-18 | Wyeth | Compositions and methods for diagnosing and treating colon cancers |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US20090233318A1 (en) | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090075304A1 (en) | 2004-05-27 | 2009-03-19 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090304679A1 (en) * | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| ES2330013T3 (es) | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
| ATE461215T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| EP2171071B1 (en) | 2007-06-15 | 2015-08-05 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
| WO2009026547A1 (en) | 2007-08-22 | 2009-02-26 | Receptor Logi, Ltd. | Methods of assaying vaccine potency |
| ES2573458T3 (es) | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
| EP2262834A4 (en) | 2008-02-27 | 2011-08-17 | Receptor Logic Inc | ANTIBODIES THAT IMITATE L-CELL RECEPTORS AND METHODS OF MAKING AND USING SAME |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| WO2009151487A1 (en) | 2008-06-13 | 2009-12-17 | Receptor Logic, Inc. | Methods of assaying vaccine potency |
| DE102008049136B4 (de) | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| US10262103B2 (en) * | 2008-11-18 | 2019-04-16 | Raphael LEHRER | Individualized cancer treatment |
| WO2011060329A1 (en) | 2009-11-14 | 2011-05-19 | Kuang-Yuh Chyu | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| US9205139B2 (en) | 2010-11-12 | 2015-12-08 | Cardiovax, Llc | Immunomodulatory methods and systems for treatment and/or prevention of aneurysms |
| EP2637689A2 (en) | 2010-11-12 | 2013-09-18 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
| CN103561760A (zh) | 2010-11-12 | 2014-02-05 | 赛达斯西奈医疗中心 | 包含apob100的免疫原性片段的免疫调节组合物、方法和系统 |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2013070603A1 (en) * | 2011-11-11 | 2013-05-16 | Cedars-Sinai Medical Center | Compositions and methods for treatment of kidney diseases |
| EP2788013A4 (en) * | 2011-12-09 | 2015-08-19 | Stealth Peptides Int Inc | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
| GB201208293D0 (en) | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| GB201209862D0 (en) * | 2012-06-01 | 2012-07-18 | Circassia Ltd | Cladosporium peptides |
| EP2892544A4 (en) * | 2012-09-05 | 2016-11-02 | Univ Virginia Patent Found | TARGET PEPTIDES FOR THERAPY AND DIAGNOSIS OF COLORECTAL CARCINOMAS |
| ES2603589T3 (es) | 2012-11-08 | 2017-02-28 | F. Hoffmann-La Roche Ag | Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas |
| GB201301632D0 (en) | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| WO2014160275A2 (en) * | 2013-03-14 | 2014-10-02 | Battell Memorial Institute | Biomarkers for liver fibrosis |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| CN103739667B (zh) | 2013-09-24 | 2017-08-25 | 上海宇研生物技术有限公司 | 卵巢癌特异的肿瘤抗原肽及其制备方法 |
| CA2942433C (en) | 2014-03-14 | 2023-08-01 | Immunocore Limited | Tcr libraries |
| MA49157A (fr) * | 2014-12-23 | 2021-06-02 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| US20180179283A1 (en) | 2015-06-08 | 2018-06-28 | Adicet Bio Inc. | T cell receptor like antibodies having fine specificity |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| MX2018012265A (es) | 2016-04-08 | 2019-02-07 | Adaptimmune Ltd | Receptores de celulas t. |
| PT3440106T (pt) | 2016-04-08 | 2021-09-29 | Adaptimmune Ltd | Recetores de células t |
| SG11201808750PA (en) | 2016-04-08 | 2018-11-29 | Adaptimmune Ltd | T cell receptors |
| MX395725B (es) | 2016-07-27 | 2025-03-25 | Sharp Kk | Métodos y aparatos de telecomunicaciones inalámbricas que usan etiqueta de valor de información del sistema. |
| US20200325244A1 (en) | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| JP7303750B2 (ja) | 2017-01-24 | 2023-07-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
| WO2018225732A1 (ja) | 2017-06-05 | 2018-12-13 | 国立大学法人三重大学 | Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質 |
| AU2018298422B2 (en) | 2017-07-04 | 2023-04-06 | CureVac SE | Novel nucleic acid molecules |
| US20210147550A1 (en) | 2017-08-18 | 2021-05-20 | Joshua Michael Francis | Antigen-binding proteins targeting shared antigens |
| CN111315769A (zh) | 2017-09-06 | 2020-06-19 | 加州理工学院 | 信号传导和抗原呈递双功能受体(sabr) |
| WO2019133853A1 (en) | 2017-12-28 | 2019-07-04 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared antigens |
| CN112236447B (zh) | 2018-04-19 | 2023-10-20 | 得克萨斯州大学系统董事会 | 具有mage-b2特异性的t细胞受体及其用途 |
| AU2019275072A1 (en) | 2018-05-23 | 2021-01-21 | Seattle Project Corp. | Shared antigens |
| US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US20200291116A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US20200291127A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
-
2015
- 2015-12-16 MA MA049157A patent/MA49157A/fr unknown
- 2015-12-16 KR KR1020207030041A patent/KR102435015B1/ko active Active
- 2015-12-16 HR HRP20211754TT patent/HRP20211754T1/hr unknown
- 2015-12-16 HR HRP20211580TT patent/HRP20211580T1/hr unknown
- 2015-12-16 HU HUE19170191A patent/HUE055489T2/hu unknown
- 2015-12-16 MD MDE20200298T patent/MD3626729T2/ro not_active IP Right Cessation
- 2015-12-16 LT LTEP19170191.1T patent/LT3545965T/lt unknown
- 2015-12-16 LT LTEP19199125.6T patent/LT3626731T/lt unknown
- 2015-12-16 MY MYPI2017700826A patent/MY178137A/en unknown
- 2015-12-16 MD MDE20200300T patent/MD3626731T2/ro not_active IP Right Cessation
- 2015-12-16 KR KR1020227028464A patent/KR102643923B1/ko active Active
- 2015-12-16 ES ES19199098T patent/ES2900106T3/es active Active
- 2015-12-16 KR KR1020247006647A patent/KR20240033128A/ko active Pending
- 2015-12-16 UA UAA201702214A patent/UA124331C2/uk unknown
- 2015-12-16 CR CR20210289A patent/CR20210289A/es unknown
- 2015-12-16 PL PL19199125T patent/PL3626731T3/pl unknown
- 2015-12-16 HU HUE15813809A patent/HUE046641T2/hu unknown
- 2015-12-16 PT PT191990985T patent/PT3616706T/pt unknown
- 2015-12-16 ES ES19199125T patent/ES2899425T3/es active Active
- 2015-12-16 KR KR1020207015687A patent/KR102395995B1/ko active Active
- 2015-12-16 SI SI201531736T patent/SI3616706T1/sl unknown
- 2015-12-16 MD MDE20200241T patent/MD3616706T2/ro not_active IP Right Cessation
- 2015-12-16 PE PE2021000187A patent/PE20211740A1/es unknown
- 2015-12-16 LT LTEP19199098.5T patent/LT3616706T/lt unknown
- 2015-12-16 PT PT191991017T patent/PT3626729T/pt unknown
- 2015-12-16 DK DK15813809.9T patent/DK3236985T4/da active
- 2015-12-16 HU HUE19199101A patent/HUE056087T2/hu unknown
- 2015-12-16 PL PL19170191T patent/PL3545965T3/pl unknown
- 2015-12-16 PL PL19199101T patent/PL3626729T3/pl unknown
- 2015-12-16 ES ES15813809T patent/ES2763911T5/es active Active
- 2015-12-16 HR HRP20211753TT patent/HRP20211753T1/hr unknown
- 2015-12-16 PT PT191701911T patent/PT3545965T/pt unknown
- 2015-12-16 SG SG10202102698VA patent/SG10202102698VA/en unknown
- 2015-12-16 MA MA050819A patent/MA50819A/fr unknown
- 2015-12-16 SG SG10202101444UA patent/SG10202101444UA/en unknown
- 2015-12-16 MA MA46913A patent/MA46913B1/fr unknown
- 2015-12-16 HR HRP20192212TT patent/HRP20192212T4/hr unknown
- 2015-12-16 PT PT191991256T patent/PT3626731T/pt unknown
- 2015-12-16 PL PL19199098T patent/PL3616706T3/pl unknown
- 2015-12-16 RS RS20211420A patent/RS62575B1/sr unknown
- 2015-12-16 SI SI201531746T patent/SI3626731T1/sl unknown
- 2015-12-16 LT LTEP19199101.7T patent/LT3626729T/lt unknown
- 2015-12-16 MD MDE20170224T patent/MD3236985T3/ro not_active IP Right Cessation
- 2015-12-16 LT LTEP15813809.9T patent/LT3236985T/lt unknown
- 2015-12-16 PT PT158138099T patent/PT3236985T/pt unknown
- 2015-12-16 MD MDE20191122T patent/MD3545965T2/ro not_active IP Right Cessation
- 2015-12-16 ES ES19170191T patent/ES2887107T3/es active Active
- 2015-12-16 MA MA49155A patent/MA49155B1/fr unknown
- 2015-12-16 ES ES19199101T patent/ES2896919T3/es active Active
- 2015-12-16 HU HUE19199098A patent/HUE057014T2/hu unknown
- 2015-12-16 HR HRP20211327TT patent/HRP20211327T1/hr unknown
- 2015-12-16 FI FIEP15813809.9T patent/FI3236985T4/fi active
- 2015-12-16 MA MA48487A patent/MA48487B1/fr unknown
- 2015-12-16 EP EP24199595.0A patent/EP4461371A3/en active Pending
- 2015-12-16 MA MA049156A patent/MA49156A/fr unknown
- 2015-12-16 HU HUE19199125A patent/HUE056607T2/hu unknown
- 2015-12-16 MY MYPI2021002573A patent/MY199068A/en unknown
- 2015-12-21 TW TW112102743A patent/TW202321273A/zh unknown
- 2015-12-21 TW TW109103806A patent/TWI754892B/zh not_active IP Right Cessation
- 2015-12-21 TW TW109139864A patent/TWI794679B/zh active
-
2017
- 2017-03-10 ZA ZA2017/01762A patent/ZA201701762B/en unknown
- 2017-04-19 CO CONC2017/0003772A patent/CO2017003772A2/es unknown
- 2017-06-21 MX MX2020011794A patent/MX2020011794A/es unknown
- 2017-06-21 MX MX2020011787A patent/MX2020011787A/es unknown
- 2017-06-21 MX MX2020005188A patent/MX2020005188A/es unknown
- 2017-06-21 MX MX2020011793A patent/MX2020011793A/es unknown
- 2017-06-21 MX MX2020004757A patent/MX2020004757A/es unknown
- 2017-06-21 MX MX2020011791A patent/MX2020011791A/es unknown
-
2019
- 2019-12-17 CY CY20191101328T patent/CY1122491T1/el unknown
-
2020
- 2020-06-12 JP JP2020102005A patent/JP7358299B2/ja active Active
- 2020-06-12 JP JP2020102004A patent/JP7109801B2/ja active Active
- 2020-06-12 JP JP2020102006A patent/JP2020191866A/ja active Pending
- 2020-06-15 JP JP2020102993A patent/JP7448423B2/ja active Active
- 2020-06-15 JP JP2020102991A patent/JP2020191867A/ja not_active Ceased
- 2020-06-15 JP JP2020102992A patent/JP7346361B2/ja active Active
- 2020-06-19 JP JP2020106475A patent/JP7026411B2/ja not_active Expired - Fee Related
-
2021
- 2021-03-23 IL IL281752A patent/IL281752A/en unknown
- 2021-06-04 CL CL2021001479A patent/CL2021001479A1/es unknown
- 2021-10-01 US US17/492,112 patent/US12076380B2/en active Active
- 2021-10-06 CY CY20211100869T patent/CY1124533T1/el unknown
- 2021-10-15 US US17/502,170 patent/US12070491B2/en active Active
- 2021-10-15 US US17/502,185 patent/US12121572B2/en active Active
- 2021-10-22 US US17/508,230 patent/US12097248B2/en active Active
- 2021-10-22 US US17/508,295 patent/US20220054613A1/en not_active Abandoned
- 2021-11-01 US US17/516,304 patent/US11576956B2/en active Active
- 2021-12-07 CY CY20211101070T patent/CY1124846T1/el unknown
- 2021-12-07 CY CY20211101071T patent/CY1124847T1/el unknown
- 2021-12-15 CY CY20211101104T patent/CY1124813T1/el unknown
-
2022
- 2022-04-25 US US17/728,756 patent/US11559573B2/en active Active
- 2022-06-29 US US17/853,334 patent/US11779638B2/en active Active
- 2022-06-29 US US17/853,344 patent/US11679147B2/en active Active
- 2022-06-29 US US17/852,623 patent/US11672848B2/en active Active
- 2022-11-09 AU AU2022268329A patent/AU2022268329A1/en not_active Abandoned
-
2023
- 2023-05-10 JP JP2023078113A patent/JP2023100927A/ja active Pending
-
2024
- 2024-08-23 US US18/814,073 patent/US20240408166A1/en active Pending
-
2025
- 2025-06-12 JP JP2025098413A patent/JP2025134788A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| HRP20201467T1 (hr) | Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom | |
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| JP2020198875A5 (enExample) | ||
| JP2020182458A5 (enExample) | ||
| AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| JP2020191862A5 (enExample) | ||
| HRP20201228T1 (hr) | Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2019516663A5 (enExample) | ||
| JP2019513005A5 (enExample) | ||
| HRP20210076T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma | |
| JP2021101700A5 (enExample) | ||
| HRP20192262T1 (hr) | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) | |
| JP2019536426A5 (enExample) | ||
| JP2019515650A5 (enExample) | ||
| JP2011520436A5 (enExample) | ||
| HRP20210528T1 (hr) | Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma | |
| HRP20230878T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003) | |
| JP2019520038A5 (enExample) | ||
| HRP20211754T1 (hr) | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova | |
| JP2020191868A5 (enExample) |